The MarketWatch News Department was not involved in the creation of this content.

December 03, 2020 (ACCESSWIRE via COMTEX) —
NEW YORK, NY / ACCESSWIRE / December 3, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Raytheon Technologies Corporation (NYSE: RTX)Class Period: February 10, 2016 – October 27, 2020Lead Plaintiff Deadline: December 29, 2020

The RTX lawsuit alleges Raytheon Technologies Corporation made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) Raytheon had inadequate disclosure controls and procedures and inadequate internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon Company’s Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice; and (6) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

Learn about your recoverable losses in RTX: http://www.kleinstocklaw.com/pslra-1/raytheon-technologies-corporation-loss-submission-form?id=11333&from=1

Zosano Pharma Corporation (NASDAQ: ZSAN)Class Period: February 13, 2017 – September 30, 2020Lead Plaintiff Deadline: December 28, 2020

The complaint alleges that during the class period Zosano Pharma Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company’s New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company’s lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ZSAN: http://www.kleinstocklaw.com/pslra-1/zosano-pharma-corporation-loss-submission-form?id=11333&from=1

Biogen Inc. (NASDAQ: BIIB)Class Period: October 22, 2019 – November 6, 2019Lead Plaintiff Deadline: January 12, 2021

Biogen Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen’s investigational human monoclonal antibody studied for the treatment of early Alzheimer’s disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in BIIB: http://www.kleinstocklaw.com/pslra-1/biogen-inc-loss-submission-form?id=11333&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:J. Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY [email protected]: (212) 616-4899Fax: (347) 558-9665www.kleinstocklaw.com

SOURCE: The Klein Law Firm

View source version on accesswire.com: https://www.accesswire.com/619338/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-RTX-ZSAN-and-BIIB

COMTEX_375471047/2457/2020-12-03T06:30:36

Is there a problem with this press release? Contact the source provider Comtex at [email protected] You can also contact MarketWatch Customer Service via our Customer Center.

Copyright 2020 ACCESSWIRE

The MarketWatch News Department was not involved in the creation of this content.

Source Article